Physicians' Academy for Cardiovascular Education
Diabetes type II confers an increased CVD risk. Recent scientific developments have yielded antidiabetic agents that positively impact CV risk in diabetic patients. Follow the latest insights into the close link between diabetes and CVD.
Many T2DM patients with established CVD and without HF are at high or very high risk for HF outcomes. Empagliflozin reduced adverse HF outcomes both in patients at low or high HF risk.
EASD 2017 The EXSCEL trial results show that treatment with exenatide extended-release did not increase the risk of MACE and may reduce all-cause mortality in T2DM patients.
EASD 2017 FOURIER sub-analysis shows that lowering LDL-C levels with evolocumab significantly and consistently reduced CV events also in patients with diabetes, without increasing the risk of new onset diabetes in non- or pre-diabetics.
In the TOSCA.IT trial, pioglitazone and sulfonylurea as add-on therapies to metformin were associated with similarly low rates of CV events and few clinically relevant side-effects in uncomplicated diabetic patients.
EASD 2017 Obese people with prediabetes or diabetes showed better glucose control and were less hungry when taking six meals per day than with three, at an identical level of total calories.
EASD 2017 In NHANES data, regularly drinking caffeinated coffee or tea was associated with lower mortality risk in women with diabetes, the protective effect varied with the source of caffeine.
EASD 2017 A posthoc analysis of data of the DUAL II and DUAL V studies showed that T2DM patients treated with insulin degludec/liraglutide had reduced CV risk factors than those treated with insulin.
EASD 2017 Two years after dieting, T2DM patients in a cognitive behavioral group therapy program showed similar weight regain and CV risk factors as those receiving standard care.
EASD 2017 Despite management by a multidisciplinary team, transgender persons with diabetes treated with hormones for gender confirmation had modifiable risk factors that aggravate diabetes.
EASD 2017 NHS provides the new, non-surgical, reversible weight loss Endobarrier device to help patients with poorly controlled T2DM and obesity kickstart a change in lifestyle.
EASD 2017 Subanalyses of EMPA-REG OUTCOME showed lower CV mortality risk in people with T2DM and established CV disease on empagliflozin treatment, irrespective of background blood sugar control.
EASD 2017 Post-hoc analysis of the SUSTAIN 1-5 trials shows that more adults with T2DM treated with semaglutide showed clinically meaningful reductions of HbA1c and body weight than those on comparator treatments.
